In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tylenol Trickles Back To Shelves As J&J Touts Consumer Turnaround

This article was originally published in The Tan Sheet

Executive Summary

J&J CEO William Weldon says the firm has “turned the corner on a particularly difficult period” that featured extensive OTC product recalls and QC issues. Worldwide consumer product sales grew slightly in the fourth quarter and full 2011.

You may also be interested in...



In Brief

Shareholder suit against Johnson & Johnson, including CFO Caruso, may proceed; Novartis pauses OTC production at Nebraska plant; Mead Johnson finds Enfamil powder clear of bacteria after stores pull the product; John Gay leaves NPA after two years as executive director and CEO; more news In Brief.

J&J Brand Revival Plan Relies On Marketing, Delivery Innovation

Johnson & Johnson expects innovation and marketing to restore consumer confidence in its OTC brands and drive a market-share rebound even as its U.S. sales continue to fall, dropping nearly 25% in its latest quarter.

Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture

Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel